Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

被引：0
|
作者：
Gabe S. Sonke
Lowell L. Hart
Mario Campone
Frans Erdkamp
Wolfgang Janni
Sunil Verma
Cristian Villanueva
Erik Jakobsen
Emilio Alba
Erik Wist
Anne M. Favret
Thomas Bachelot
Roberto Hegg
Paul Wheatley-Price
Farida Souami
Santosh Sutradhar
Michelle Miller
Caroline Germa
Howard A. Burris
机构：
[1] Netherlands Cancer Institute/BOOG Study Center,Department of Medical Oncology
[2] Florida Cancer Specialists,Zuyderland Medical Center
[3] Sarah Cannon Research Institute,University Hospital of Besançon
[4] Institut de Cancérologie de l’Ouest – René Gauducheau Centre de Recherche en Cancérologie,Virginia Cancer Specialists PC
[5] Sittard-Geleen/Heerlen,Ottawa Hospital Research Institute
[6] Universitätsklinikum Ulm,undefined
[7] Tom Baker Cancer Centre,undefined
[8] Hospital Jean-Minjoz,undefined
[9] Lillebælt Hospital,undefined
[10] Hospital Universitario Virgen de la Victoria,undefined
[11] IBIMA,undefined
[12] Oslo University Hospital,undefined
[13] US Oncology,undefined
[14] Centre Léon Bérard,undefined
[15] Hospital Pérola Byington Centro de Referência da Saúde da Mulher,undefined
[16] University of Ottawa,undefined
[17] Novartis Pharma AG,undefined
[18] Novartis Pharmaceuticals Corporation,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 167卷
关键词：
Breast cancer; CDK inhibitor; Ribociclib; Endocrine therapy; Elderly; Hormone receptor-positive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：659 / 669
页数：10
相关论文
共 50 条
  • [31] A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer
    Christos Vaklavas
    Erica M. Stringer-Reasor
    Ahmed M. Elkhanany
    Kevin J. Ryan
    Yufeng Li
    Charles P. Theuer
    Edward P. Acosta
    Shi Wei
    Eddy S. Yang
    William E. Grizzle
    Andres Forero-Torres
    Breast Cancer Research and Treatment, 2023, 198 : 217 - 229
  • [32] Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2
    Verma, Sunil
    O'Shaughnessy, Joyce
    Burris, Howard A.
    Campone, Mario
    Alba, Emilio
    Chandiwana, David
    Dalal, Anand A.
    Sutradhar, Santosh
    Monaco, Mauricio
    Janni, Wolfgang
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (03) : 535 - 545
  • [33] Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
    Gabriel N. Hortobagyi
    Breast Cancer Research, 20
  • [34] Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
    Hortobagyi, Gabriel N.
    BREAST CANCER RESEARCH, 2018, 20
  • [35] Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
    Burris, Howard A.
    Chan, Arlene
    Bardia, Aditya
    Thaddeus Beck, J.
    Sohn, Joohyuk
    Neven, Patrick
    Tripathy, Debu
    Im, Seock-Ah
    Chia, Stephen
    Esteva, Francisco J.
    Hart, Lowell
    Zarate, Juan Pablo
    Ridolfi, Antonia
    Lorenc, Karen Rodriguez
    Yardley, Denise A.
    BRITISH JOURNAL OF CANCER, 2021, 125 (05) : 679 - 686
  • [36] Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2
    Pritchard, Kathleen I.
    Burris, Howard A., III
    Ito, Yoshinori
    Rugo, Hope S.
    Dakhil, Shaker
    Hortobagyi, Gabriel N.
    Campone, Mario
    Csoszi, Tibor
    Baselga, Jose
    Puttawibul, Puttisak
    Piccart, Martine
    Heng, Daniel
    Noguchi, Shinzaburo
    Srimuninnimit, Vichien
    Bourgeois, Hugues
    Gonzalez Martin, Antonio
    Osborne, Karen
    Panneerselvam, Ashok
    Taran, Tetiana
    Sahmoud, Tarek
    Gnant, Michael
    CLINICAL BREAST CANCER, 2013, 13 (06) : 421 - U113
  • [37] Maintenance of health-related quality of life in elderly patients treated with ribociclib plus letrozole in MONALEESA-2
    Burris, Howard A.
    Tolaney, Sara M.
    Hart, Lowell L.
    Favret, Anne
    Alemany, Carlos A.
    Volas-Redd, Gena H.
    Shtivelband, Mikhail
    Chandiwana, David
    Das Purkayastha, D.
    Caria, Nicola
    Baeck, Johan
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative, advanced breast cancer (ABC) who received no prior therapy for advanced disease
    Janni, W.
    Nusch, A.
    Grischke, E. -M
    Marschner, N.
    Wilke, J.
    Decker, T.
    Abenhardt, W.
    Kurbacher, C.
    Overkamp, F.
    Just, M.
    Kuemmel, S.
    Marme, F.
    Xuan, F.
    Miller, M.
    Sonke, G. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 214 - 215
  • [39] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [40] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
12345